Patch Technologies

The ViaDor^TM system incorporates a patch containing a drug that is applied following the formation of the RF-MicroChannels. TransPharma Medical's formulation team has gained vast experience and expertise to efficiently formulate compounds to be delivered using the ViaDor system.

Breakthroughs in Drug Patch Technology

TransPharma Medical has developed two proprietary dry form Patch Technologies for transdermal delivery of proteins, peptides and small molecules, which complement its ViaDor delivery technology:

•     Printed Patch – yields  a peak blood profile
•     Film Patch –  yields a prolonged blood profile

The printed patch consists of a thin layer of evenly deposited drug formulation in a dry form on the surface of the patch that interfaces with the skin.
The film patch consists of a layer of drug formulation incorporated in a dry hydrogel based matrix. 

 The drug in both patch types stay in its dry form right up until the time it is administered. The dry state improves stability and thus extends the product's shelf life. As soon as the printed patch is applied on the skin where RF MicroChannles have just been formed by the ViaDor device, interstitial fluid released by the body through the MicroChannels comes in contact with the dry drug layer and dissolves it to form a saturated solution, now entering the inner skin layers with an extremely sharp concentration gradient, resulting in a peak blood profile. In a similar manner, in case of the film patch, a high concentration drug gel is formed in-situ, which attenuates the drug molecule movement, thus enabling an extended delivery profile. 

TransPharma’s proprietary dry form patch technologies bring together the advantages of a dry dosage form and the special features of the hydrophilic channels. These technologies were specifically developed to provide a solution to the challenge of transdermal delivery of proteins and other macromolecules.